We aren’t simply a third party, we’re an active partner.
We’re experienced at recognizing great ideas and impassioned innovators. Just as importantly, we’re fellow entrepreneurs who realize that smart investing, and success, is never a single step in the journey, but many steps taken together in partnership.
“Aratana Therapeutics started as a concept: a pharmaceutical company focused on pets. Given a long-standing relationship with Jay Lichter [through a prior investment in Syndax Pharmaceuticals] and Avalon’s status as a leader in venture capital, it was a natural fit. Jay assumed the role of Chairman of the Board, and he was a terrific partner to me as a first time CEO eventually taking the company public and pioneering the pet therapeutics industry.”
Steven St. Peter
Managing Director of VIE Ventures
“Avalon understands there will be unexpected challenges and that success will be determined by how management teams overcome issues. They have always been a supportive and active partner, contributing their extensive experience and knowledge to help us solve problems and achieve our goals.”
David Weber, Ph.D.
President and CEO of Otonomy, Inc.
“Avalon has enabled the creation of Fortis Therapeutics, Inc., which turned a discovery made in my lab into two multi-center phase I clinical trials in about two years. It has been a great experience to work with Avalon. They have provided both strong financial support and an outstanding management team to enable timely translation of laboratory research to the clinic.”
Bin Liu, Ph.D.
Professor, UCSF and Founder of Fortis, Inc.
“Collaborating with the team from Avalon has been a complete success. The use of the accelerator allowed for rapid and cost effective development of our asset ultimately lead to an acquisition of the novel drug candidate to treat patients with celiac disease.”
Chaitan Khosla, Ph.D.
Professor, Stanford and Founder of Sitari, Inc.
“Avalon’s founding and unwavering commitment to Synthorx along with their contributions to the financing and strategy of the company was paramount to our ability to execute.”